Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes >/=65 and <65 Years of Age: A Pooled Analysis from Phase III Studies.

MLA

Bode BW, et al. “Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes >/=65 and <65 Years of Age: A Pooled Analysis from Phase III Studies.” American Journal of Geriatric Pharmacotherapy, vol. 9, no. 6, Dec. 2011, pp. 423–33. EBSCOhost, https://doi.org/10.1016/j.amjopharm.2011.09.007.

APA

Bode BW, Brett J, Falahati A, & Pratley RE. (2011). Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes >/=65 and <65 Years of Age: A Pooled Analysis from Phase III Studies. American Journal of Geriatric Pharmacotherapy, 9(6), 423–433. https://doi.org/10.1016/j.amjopharm.2011.09.007

Chicago

Bode BW, Brett J, Falahati A, and Pratley RE. 2011. “Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes >/=65 and <65 Years of Age: A Pooled Analysis from Phase III Studies.” American Journal of Geriatric Pharmacotherapy 9 (6): 423–33. doi:10.1016/j.amjopharm.2011.09.007.